Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
(Thomson Reuters ONE) -
Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE:
TRVX), a clinical stage company focused on developing immuno-oncology therapies
to target treatment-resistant solid tumors, today announces that it presented
clinical data from the phase I/II clinical trial evaluating TG01 in resected
pancreatic cancer in a poster presentation at the American Society of Clinical
Oncology Annual Meeting 2017 (ASCO) on Saturday, June 3(rd) 2017.
The study evaluated safety, immunological response and overall survival of
TG01/GM-CSF and gemcitabine as an adjuvant therapy for treating patients with
resected RAS-mutant adenocarcinoma of the pancreas. The data show that:
* TG01/GM-CSF generated early immune responses in 89% of patients (17/19) with
resected pancreatic cancer. 95% of patients (18/19) showed immune activation
in either DTH and/or PBMC tests. This demonstrates that TG01 vaccination
activates mutant RAS specific T cells
* Overall survival was encouraging in view of published reports with a median
overall survival of 33.1 months
* The regimen was generally well tolerated although some late, manageable
allergic reactions were seen
Magnus Jaderberg MD, Chief Medical Officer of Targovax, said, "These data
provide support of TG01-immunotherapy for the treatment of resected pancreatic
cancer. This is a key milestone for Targovax and we look forward to defining the
next step in development for this combination therapy. Targovax is also
evaluating TG02, the second TG cancer immune activator, in colorectal cancer. We
recently announced the initiation of this phase Ib trial, and the readout
expected in the second half of 2018 will provide important mechanistic data, not
just for TG02, but for the entire TG technology platform."
Please see the poster attached.
***
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli(at)targovax.com
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff(at)crux.no
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax(at)fticonsulting.com
About TG01
TG01 is an injectable antigen-specific cancer immunotherapy targeted to treat
patients with KRAS mutations, found in more than 85% of pancreatic
adenocarcinomas. TG01 consists of a mixture of 7 synthetic peptides that
represent 7 of the most common codon 12 and 13 mutations in p21RAS associated
with human cancer. TG01 induces RAS mutant-specific T-cell responses which are
enhanced by co-administration of GM-CSF (recombinant human granulocyte
macrophage-colony stimulating factor). TG01 was the first therapeutic peptide
vaccine targeting RAS that entered clinical trials. Earlier studies demonstrate
that adjuvant vaccination with TG01/GM-CSF given as monotherapy to pancreatic
cancer patients after tumor resection induce immune response in 100% of
patients.
About Targovax
Arming the patient's immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing
novel immuno-oncology therapies to target, primarily, treatment-resistant solid
tumors. Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
The Company's development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of
biological therapy. ONCOS exclusively uses an adenovirus that has been
engineered to be an immune activator that selectively target cancer cells. In
phase I it has shown to immune activate at lesional level which was associated
with clinical benefit. We expect proof of concept data for this platform in
2017 from a clinical trial of lead product ONCOS-102 in patients with refractory
malignant melanoma.
The second platform, TG peptides (TG), solely targets tumors that express
mutated forms of the RAS protein. Mutations to this protein are common in many
cancers and are known to drive aggressive disease progression and treatment
resistance. There is a high unmet medical need for therapies that are effective
against tumors that express these mutations. The TG platform's therapeutic
potential stems from its ability to enable a patient's immune system to identify
and then destroy tumors bearing any RAS mutations. In early 2017, key proof of
concept data for the TG platform from a clinical trial of TG01 in resected
pancreatic cancer patients showed encouraging overall survival and will give
guidance for the future clinical development of this platform.
Targovax's development pipeline has three novel therapeutic candidates in
clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. Additionally, we have other products in early stages of development.
In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the
shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Targovax ASCO poster 2017:
http://hugin.info/171039/R/2110562/802157.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.06.2017 - 07:01 Uhr
Sprache: Deutsch
News-ID 546357
Anzahl Zeichen: 6428
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 280 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
